Outlook Therapeutics (OTLK) Preferred Stock Liabilities (2017 - 2020)

Outlook Therapeutics (OTLK) has 4 years of Preferred Stock Liabilities data on file, last reported at $6.5 million in Q1 2020.

• Preferred Stock Liabilities for Q1 2020 came in at $6.5 million, up 28.34% year-over-year; the trailing twelve-month figure through Mar 2020 was $6.5 million (up 28.34% YoY), and the FY2019 annual result was $5.4 million, up 13.2% from the prior year.
• Preferred Stock Liabilities eased to $6.5 million in Q1 2020 per OTLK's latest filing, from $8.3 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $18.3 million in Q1 2018 and troughed at $2.9 million in Q3 2017.
• A 4-year average of $7.5 million and a median of $5.2 million in 2019 frame the typical range for Preferred Stock Liabilities.
• On a YoY basis, Preferred Stock Liabilities climbed as much as 69.91% in 2019 and fell as far as 72.46% in 2019.
• A 4-year view of Preferred Stock Liabilities shows it stood at $17.2 million in 2017, then slumped by 71.58% to $4.9 million in 2018, then soared by 69.91% to $8.3 million in 2019, then decreased by 22.08% to $6.5 million in 2020.
• Business Quant data shows OTLK's Preferred Stock Liabilities at $6.5 million in Q1 2020, $8.3 million in Q4 2019, and $5.4 million in Q3 2019.